Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

2012 are primarily due to a $25.0 million milestone achieved upon the acceptance of the naloxegol MAA filing in Europe as well as increased product sales.  In addition, revenue in the first nine months of 2013 increased as compared to the same period in 2012 due to a $10.0 million milestone achieved upon the initiation of Phase 3 studies for Amikacin Inhale in April 2013.

Total operating costs and expenses in the third quarter of 2013 were $67.4 million as compared to $51.3 million in the third quarter of 2012.  Year-to-date total operating costs and expenses in 2013 were $202.0 million as compared to $157.9 million for the same period in 2012.  Total operating costs and expenses increased primarily as a result of increased clinical development expenses.

Research and development expenses in the third quarter of 2013 were $43.9 million as compared to $34.0 million in the third quarter of 2012.  Year-to-date R&D expense for 2013 was $141.8 million as compared to $102.3 million for the same period in 2012.  R&D expense was higher in the third quarter and the first nine months of 2013 as compared to the same periods in 2012 reflecting the costs of the Phase 3 study of etirinotecan pegol (NKTR-102) in metastatic breast cancer, the Phase 2 study of NKTR-181, preparation for the Phase 3 study of NKTR-181, the Phase 1 study of NKTR-192, and the production of devices for the Phase 3 study of Amikacin Inhale.

General and administrative expense was $10.6 million in the third quarter of 2013 as compared to $10.1 million in the third quarter of 2012.  G&A expense in the first nine months of 2013 was $30.7 million as compared to $30.8 million for the same period in 2012.

Non-cash interest expense incurred in connection with the 2012 royalty monetization was $5.6 million and $16.6 million in the third quarter and first nine months of 2013, respectively, as compared to $5.5 million and $12.6 million in the
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... March 30, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... The live presentation takes place on Wednesday, ... a.m. Pacific Time.  The presentation will be webcast and may ...
... 2011 CANTEL MEDICAL CORP. (NYSE: ... President, will be presenting at the Needham & Company, LLC ... 4:00 PM EDT on Wednesday, April 6, 2011 at the ... immediately following the presentation.  In addition, Mr. Segel will be ...
Cached Medicine Technology:
(Date:8/1/2014)... -- Almost 140 people die every year in ... States. But there are several simple ways ... prevention coordinator at Cincinnati Children,s Hospital Medical Center,s ... center news release. "As families begin to ... for parents and children to go over school ...
(Date:8/1/2014)... Illinois (PRWEB) August 01, 2014 As ... across the country, Ronald E. Johnson, Jr. has been ... by AndroGel and other testosterone medications. Since the Fall ... Johnson, P.S.C. have worked diligently to investigate and prosecute ... pulmonary embolisms, and blood clots as a result of ...
(Date:8/1/2014)... August 01, 2014 Market Publishers ... reports have been added to its catalogue. ... Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services ... pharma industry drivers include, among others, increasing ageing ... hygiene. In 2015, the pharma market in India ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... a time-honored destination for a good cut and conversation. ... be the spot to tackle an often overlooked health concern: ... partnership, the U.S. Centers for Disease Control and Prevention, together ... help of barbershop staff to both discuss and diagnose high ...
(Date:8/1/2014)... 2014 Over the past five ... innovative technologies that have enabled cosmetic dentists to ... color. Moreover, the burgeoning elderly population has stimulated ... ailments. Due to long-term use of medications, which ... demanded dental fillings, veneers and implants. As more ...
Breaking Medicine News(10 mins):Health News:Expert Offers School Bus Safety Tips 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... also available in Chinese ., , ... side effects of chemotherapy in cancer patients by stimulating ... in mice suggests., The research will appear in the ... which is published by AAAS, the nonprofit science ...
... A paper by Indiana University-Purdue University Indianapolis ... to improve identification of breast cancer tissue by ... scientific paper in the "bioinformatics and biomedical applications ... The best scientific paper award ...
... WEDNESDAY, Aug. 18 (HealthDay News) -- With their enticing cool ... the most controversial products made by the tobacco industry. ... of smokers aged 12 to 17 using menthol cigarettes, according ... Most black teenaged smokers -- and 82.7 percent of black ...
... Center in Israel have determined that the use ... outcome for patients undergoing percutaneous coronary intervention (PCI), ... appear in the September issue of Catheterization ... Wiley-Blackwell on behalf of The Society for Cardiovascular ...
... Aug. 19, 2010 A pediatric urologist at UT ... for young girls who have absent or malformed vaginas, ... Unknown causes and certain genetic disorders can cause ... other birth defects that can accompany the vaginal problems, ...
... To improve the quality of HIV care and treatment ... and monitoring of antiretroviral therapy should be adopted uniformly, according ... The work group,s study results appear in the current ... study shows how national HIV quality performance measures were developed, ...
Cached Medicine News:Health News:Ancient Chinese medicine may help chemotherapy patients 2Health News:FDA Mulling Ban on Menthol Cigarettes 2Health News:FDA Mulling Ban on Menthol Cigarettes 3Health News:FDA Mulling Ban on Menthol Cigarettes 4Health News:Drug-eluting stents confirmed safe, effective for long-term use 2Health News:Pediatric urologist performs innovative procedure for girls with rare vaginal defects 2Health News:Uniform, national measures should define HIV/AIDS care 2
... Parathyroid hormone (PTH) is synthesized ... secreted in response to decreased extracellular ... enhancing bone resorption and decreasing calcium ... into the circulation, intact PTH is ...
... the adrenal cortex and, to a lesser ... a precursor in testosterone and estrogen synthesis, ... at ~10% that of testosterone [1]. However, ... women, DHEA is an important androgen as ...
... steroid, is one of the most potent ... testosterone is secreted primarily by the testes ... peripheral conversion of androstenedione [2]. In adult ... 50% of serum testosterone is derived from ...
... Thyroxine (T4) is the primary active ... the thyroid gland [1]. T4 is synthesized ... iodide trapping by the follicular cells, (ii) ... substrate leading to formation of 3-monoiodotyrosine and ...
Medicine Products: